- Home
- CTLT
CTLT
Catalent Inc.
as 11-15-2024 4:00pm EST
Catalent is a contract development and manufacturing organization, or CDMO. It operates under four segments: biologics, softgel and oral technologies, oral and specialty delivery, and clinical supply services. Catalent derives its revenues primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products throughout the entire life cycle of a product from the drug development process to commercial supply. Catalent has over 50 facilities across four continents.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | SOMERSET |
| Market Cap: | 11.0B | IPO Year: | 2014 |
| Target Price: | $59.83 | AVG Volume (30 days): | 1.9M |
| Analyst Decision: | Hold | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.28 | EPS Growth: | N/A |
| 52 Week Low/High: | $36.74 - $61.20 | Next Earning Date: | 11-05-2024 |
| Revenue: | $4,422,000,000 | Revenue Growth: | 4.71% |
| Revenue Growth (this year): | 8.58% | Revenue Growth (next year): | 7.95% |
Stock Insider Trading Activity of Catalent Inc. (CTLT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Ferraro Joseph Anthony | CTLT | SVP, General Counsel, CCO | Oct 18 '24 | Sell | $59.97 | 320 | $19,190.40 | 23,967 | |
| McErlane David | CTLT | Group President, Biologics | Sep 26 '24 | Sell | $59.97 | 1,994 | $119,580.18 | 36,304 |
Latest Catalent Inc. News
CTLT Breaking Stock News: Dive into CTLT Ticker-Specific Updates for Smart Investing
Reuters
4 days ago
EU regulators quiz Novo Nordisk, Catalent rivals on $16.5 billion deal
Zacks
4 days ago
JAZZ or CTLT: Which Is the Better Value Stock Right Now?
Argus Research
5 days ago
CTLT: Raising target price to $62.00
Zacks
11 days ago
Catalent's Stock Gains Despite Q1 Earnings Miss, Gross Margin Up
Argus Research
12 days ago
CTLT: Lowering target price to $61.00
Morningstar Research
12 days ago
Analyst Report: Catalent, Inc.
MT Newswires
12 days ago
Catalent Fiscal Q1 Net Loss Flat, Revenue Gains
Reuters
12 days ago
Catalent misses Q1 revenue estimates ahead of $16.5 billion deal close with Novo Holdings
Compare CTLT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CTLT Catalent Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.